Humulin R + Kanglaite Injection

Humulin R + Kanglaite Injection is a combination or co-administration of Humulin R (a short-acting recombinant human insulin) and Kanglaite Injection (KLT), a botanical drug derived from the seeds of *Coix lacryma-jobi* (Job's tears). Kanglaite is formulated as an oil-in-water emulsion containing neutral lipids (triglycerides) and is used primarily in China for the treatment of various solid tumors, including non-small cell lung cancer, hepatocellular carcinoma, and pancreatic cancer. Its mechanism involves inducing apoptosis, inhibiting mitosis at the G2/M phase, and suppressing angiogenesis. Humulin R is a standard insulin therapy used to regulate glucose metabolism. In the context of oncology, insulin is sometimes explored for its potential to sensitize tumor cells to treatment or to manage metabolic effects associated with high-lipid loads or cancer-related cachexia. The provided clinical trial context specifically highlights a Phase I study of Kanglaite Injection (KLT) conducted by KangLaiTe USA to evaluate safety, maximum tolerated dose, and pharmacokinetics in patients with refractory solid tumors.

Brand names

Kanglaite

Other names

Coix seed oil injectionKLT InjectionInsulin HumanHumulin R U-100